Key insights
- UBS maintained a Neutral rating on Moderna (MRNA), citing a Phase III melanoma trial interim analysis in 2026 as a key catalyst. While a positive outcome could boost the stock 25-50%, the firm acknowledges potential delays. The trial, partnered with Merck, is crucial for de-risking Moderna's INT program. Other news includes bylaw amendments and successful stockholder meeting outcomes.
Investing.com - UBS reiterated a Neutral rating and $45.00 price target on Moderna Inc. (NASDAQ:MRNA) shares. The stock currently trades at $47.38, up 78% over the past year, though InvestingPro analysis suggests the shares may be overvalued relative to its Fair Value estimate.
The firm cited the company’s Phase III INT adjuvant melanoma interim analysis as a major catalyst for 2026. Moderna has guided the interim analysis to occur in 2026, with UBS estimating a potential timeframe around October or November.
UBS assigned a probability of success above 50% for the interim analysis. The firm noted the stock could move 25% to 50% higher if the interim analysis meets its endpoint.
The firm acknowledged a scenario where the study does not stop for interim analysis and would require waiting for the final analysis. UBS stated this could occur if more time is needed for the survival curves to separate.
The INT program is partnered with Merck and is being conducted in renal cell carcinoma, non-small cell lung cancer, and other indications. UBS expressed a positive view on the adjuvant melanoma study and described it as the first step needed to de-risk the INT program. For deeper insights into Moderna’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro alongside analysis of 1,400+ other US equities.
In other recent news, Moderna has announced significant developments that have caught the attention of investors. The company reported an amendment to its bylaws, designating federal district courts as the exclusive forum for resolving complaints under the Securities Act of 1933. This change aligns with recent amendments to the General Corporation Law of the State of Delaware. Additionally, Moderna held its 2026 Annual Meeting of Stockholders, where all agenda items were successfully voted on with a quorum present.
Furthermore, Moderna revealed plans for early-stage research into an mRNA-based hantavirus vaccine, which has been confirmed in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University. This research initiative is part of the company’s mRNA Access Program. The World Health Organization recently reported 11 cases of hantavirus, including three fatalities, among passengers and crew on a cruise ship, although a wider outbreak is not expected.
These developments underscore Moderna’s ongoing efforts in vaccine research, particularly in response to emerging health concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.